hydroxychloroquine has been researched along with Carcinoma, Basal Cell in 1 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Carcinoma, Basal Cell: A malignant skin neoplasm that seldom metastasizes but has potentialities for local invasion and destruction. Clinically it is divided into types: nodular, cicatricial, morphaic, and erythematoid (pagetoid). They develop on hair-bearing skin, most commonly on sun-exposed areas. Approximately 85% are found on the head and neck area and the remaining 15% on the trunk and limbs. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1471)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To characterise the incidence rate of skin cancer associated with methotrexate and hydroxychloroquine in older adults with rheumatoid arthritis (RA)." | 8.31 | Risk of malignant melanoma and non-melanoma skin cancer in rheumatoid arthritis patients initiating methotrexate versus hydroxychloroquine: a cohort study. ( Chen, SK; Desai, RJ; Gautam, N; Glynn, RJ; He, M; Kim, SC; Lee, H; Vine, SM; Weinblatt, ME, 2023) |
| "To characterise the incidence rate of skin cancer associated with methotrexate and hydroxychloroquine in older adults with rheumatoid arthritis (RA)." | 4.31 | Risk of malignant melanoma and non-melanoma skin cancer in rheumatoid arthritis patients initiating methotrexate versus hydroxychloroquine: a cohort study. ( Chen, SK; Desai, RJ; Gautam, N; Glynn, RJ; He, M; Kim, SC; Lee, H; Vine, SM; Weinblatt, ME, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, H | 1 |
| Chen, SK | 1 |
| Gautam, N | 1 |
| Vine, SM | 1 |
| He, M | 1 |
| Desai, RJ | 1 |
| Weinblatt, ME | 1 |
| Glynn, RJ | 1 |
| Kim, SC | 1 |
1 other study available for hydroxychloroquine and Carcinoma, Basal Cell
| Article | Year |
|---|---|
Risk of malignant melanoma and non-melanoma skin cancer in rheumatoid arthritis patients initiating methotrexate versus hydroxychloroquine: a cohort study.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; | 2023 |